NCT02524665 is a Phase 4 clinical trial of MAXCLARITY II (2.5% BPO) Foam Cleanser in Acne Vulgaris, sponsored by Stiefel, a GSK Company.

Who is sponsoring NCT02524665?

NCT02524665 is sponsored by Stiefel, a GSK Company.

What drugs are being tested in NCT02524665?

Interventions in NCT02524665: MAXCLARITY II (2.5% BPO) Foam Cleanser, MAXCLARITY II (2.5% BPO) Foam Treatment, MAXCLARITY II (0.5% Salicylic Acid) Toner Foam, MURAD Clarifying Cleanser (1.5% SA), Exfoliating Acne Treatment Gel (1% SA), Skin Perfecting Lotion.

What condition does NCT02524665 study?

NCT02524665 studies Acne Vulgaris.

Is NCT02524665 still recruiting?

NCT02524665 is currently completed. Last updated 16 March 2017.

Are results published for NCT02524665?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-03-16 · How we verify

NCT02524665

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects With Acne

Completed Phase 4 Results posted Last updated 16 March 2017

What this trial tests

Phase 4 trial testing MAXCLARITY II (2.5% BPO) Foam Cleanser in Acne Vulgaris in 20 participants. Completed in 1 December 2009.

Timeline

1 September 2009

Primary endpoint
1 December 2009

1 December 2009

Quick facts

Lead sponsor	Stiefel, a GSK Company
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	1 September 2009
Primary completion	1 December 2009
Estimated completion	1 December 2009

Drugs / interventions tested

MAXCLARITY II (2.5% BPO) Foam Cleanser — full drug profile →
MAXCLARITY II (2.5% BPO) Foam Treatment — full drug profile →
MAXCLARITY II (0.5% Salicylic Acid) Toner Foam — full drug profile →
MURAD Clarifying Cleanser (1.5% SA)
Exfoliating Acne Treatment Gel (1% SA)
Skin Perfecting Lotion

Conditions studied

Acne Vulgaris — all drugs for Acne Vulgaris →

Sponsor

Stiefel, a GSK Company — full company profile →

Who can join

Adults 16 to 29, any sex, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mean Percent Change in Inflammatory, Non-inflammatory and Total Lesion Counts From Baseline to Week 8.
Time frame: Baseline and Week 8
During each study visit, expert grader (blinded evaluator) assessed the left side and right side of the face as inflammatory (papules \[solid elevation of skin with no visible fluid\] and pustules \[small inflamed elevation of the skin that is filled with pus\]) and non-inflammatory (open \[blackheads\] and closed \[whiteheads\] comedones) and total lesions for each participant. Each type of lesio

Sponsor's own description

One of the main success factors in acne therapy is user compliance with treatment, product cost, availability and ease of use. Poor compliance may translate into decreased efficacy (either not improving symptoms well enough or not improving symptoms fast enough), tolerability issues or adverse effects (eg, erythema, dryness, or peeling of the skin), a lack of understanding of the instructions for use, or product cost/availability. Whatever the reason, poor compliance translates to decreased efficacy and increased frustration on the part of the user. The current study will evaluate and compare the efficacy and tolerability of 2 over the counter, topical product lines for the treatment of acne: MAXCLARITY II Foam Cleanser (2.5% benzoyl peroxide \[BPO\]) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam compared with MURAD Clarifying Cleanser (1.5% salicylic acid \[SA\]) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Topical benzoyl peroxide for acne.
Yang Z, Zhang Y, Lazic Mosler E, Hu J, et al · · 2020 · cited 29× · PMID 32175593 · DOI 10.1002/14651858.cd011154.pub2

Verify or expand the search:

Other trials of MAXCLARITY II (2.5% BPO) Foam Cleanser

Trials testing the same drug.

NCT01706250 — U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PRO · Phase 4 · completed
NCT01706263 — U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne · Phase 4 · completed

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
NCT07056673 — Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study · NA · recruiting
NCT07102186 — Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris · Phase 4 · recruiting

Other Stiefel, a GSK Company trials

Trials by the same sponsor.

NCT02673619 — A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis · Phase 2 · completed
NCT02411162 — A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream · Phase 1 · completed
NCT02014584 — Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia · Phase 3 · completed
NCT01984775 — A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects · Phase 1 · completed
NCT01446237 — U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, S · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02524665 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Stiefel, a GSK Company
Last refreshed: 16 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02524665.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing